Xenon Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Shareholders held by Xenon Pharmaceuticals Inc. on June 1, 2023. The filing details the voting results for four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Approximately 83.65% of total common shares entitled to vote were present or represented by proxies. All four proposals were approved:
- Proposal One (Election of Directors): All eight nominees were elected. The highest "Against" vote was received by Patrick Machado (2,355,359 votes), while the lowest was Steven Gannon (187,853 votes).
- Proposal Two (Say-on-Pay): Advisory approval of executive compensation was granted with 44,167,661 votes "For" and 6,700,364 votes "Against."
- Proposal Three (Appointment of Auditor): KPMG LLP was appointed as the independent registered public accounting firm with 51,532,487 votes "For" and 1,265,871 votes "Withheld."
- Proposal Four (Remuneration of Auditor): Authority for the audit committee to set auditor remuneration was approved with 50,683,345 votes "For" and 284,460 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the "Against" votes on director elections, particularly for Patrick Machado and Gary Patou, which exceeded 2 million votes each.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 27, 2023, for detailed descriptions of the proposals and executive compensation details.
- Confirm the tenure of the newly elected directors, which extends until the 2024 annual meeting.